Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Feb;18(2):411-421.
doi: 10.1111/jth.14662. Epub 2019 Nov 28.

Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial

Robert D McBane 2nd  1   2   3 , Waldemar E Wysokinski  1   2   3 , Jennifer G Le-Rademacher  4 , Tyler Zemla  4 , Aneel Ashrani  1   2 , Alfonso Tafur  5 , Usha Perepu  6 , Daniel Anderson  7 , Krishna Gundabolu  8 , Charles Kuzma  9 , Juliana Perez Botero  10 , Roberto A Leon Ferre  11 , Stanislav Henkin  12 , Charles J Lenz  1   3 , Damon E Houghton  1   2   3 , Prakash Vishnu  13 , Charles L Loprinzi  11
Affiliations
Free article
Randomized Controlled Trial

Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial

Robert D McBane 2nd et al. J Thromb Haemost. 2020 Feb.
Free article

Abstract

Background: Low-molecular-weight heparin is the guideline-endorsed treatment for cancer-associated venous thromboembolism (VTE). While apixaban is approved for the treatment of acute VTE, limited data support its use in cancer patients.

Objectives: The primary outcome was major bleeding. Secondary outcomes included VTE recurrence and a composite of major plus clinically relevant non-major bleeding (CRNMB).

Patients/methods: Patients with cancer-associated VTE were randomly assigned to receive either apixaban 10 mg twice daily for seven days followed by 5 mg twice daily for six months or subcutaneous dalteparin (200 IU/kg for one month followed by 150 IU/kg once daily).

Results: Of 300 patients randomized, 287 were included in the primary analysis. Metastatic disease was present in 66% of subjects; 74% were receiving concurrent chemotherapy. Major bleeding occurred in 0% of 145 patients receiving apixaban, compared with 1.4% of 142 patients receiving dalteparin [P = .138; hazard ratio (HR) not estimable because of 0 bleeding event in apixaban group]. Recurrent VTE occurred in 0.7% of apixaban, compared to 6.3% of dalteparin patients [HR 0.099, 95% confidence interval [CI], 0.013-0.780, P = .0281). Major bleeding or CRNMB rates were 6% for both groups.

Conclusions: Oral apixaban was associated with low major bleeding and VTE recurrence rates for the treatment of VTE in cancer patients.

Trial registration: ClinicalTrials.gov NCT02585713.

Keywords: apixaban; bleeding; cancer; dalteparin; venous thromboembolism.

PubMed Disclaimer

References

REFERENCES

    1. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-815.
    1. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632-634.
    1. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846-1850.
    1. Chee CE, Ashrani AA, Marks RS, et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood. 2014;123:3972-3978.
    1. Trujillo-Santos J, Nieto JA, Ruíz-Gamietea A, et al. Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res. 2010;125(suppl 2):S58-S61.zzX z

Publication types

Associated data

LinkOut - more resources